MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.metabol.2024.155915

Медицинская библиотека · Metabolism: clinical and experimental · 2024

Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms.

Richter Michael M, Kemp Ida M, Heebøll Sara, Winther-Sørensen Marie, Kjeldsen Sasha A S, Jensen Nicole J, Nybing Janus D, Linden Frederik H, Høgh-Schmidt Erik, Boesen Mikael P, Madsbad Sten, Schiødt Frank Vinholt, Nørgaard Kirsten, Schmidt Signe, Gluud Lise Lotte, Haugaard Steen B, Holst Jens J, Nielsen Søren, Rungby Jørgen, Wewer Albrechtsen Nicolai J

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Glucagon receptor agonism is currently explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The metabolic effects of glucagon receptor agonism may in part be mediated by increases in circulating levels of Fibroblast Growth Factor 21 (FGF21) and Growth Differentiation Factor 15 (GDF15). The effect of glucagon agonism on FGF21 and GDF15 levels remains uncertain, especially in the context of elevated insulin levels commonly observed in metabolic diseases.

METHODS

We investigated the effect of a single bolus of glucagon and a continuous infusion of glucagon on plasma concentrations of FGF21 and GDF15 in conditions of endogenous low or high insulin levels. The studies included individuals with overweight with and without MASLD, healthy controls (CON) and individuals with type 1 diabetes (T1D). The direct effect of glucagon on FGF21 and GDF15 was evaluated using our in-house developed isolated perfused mouse liver model.

RESULTS

FGF21 and GDF15 correlated with plasma levels of insulin, but not glucagon, and their secretion was highly increased in MASLD compared with CON and T1D. Furthermore, FGF21 levels in individuals with overweight with or without MASLD did not increase after glucagon stimulation when insulin levels were kept constant. FGF21 and GDF15 levels were unaffected by direct stimulation with glucagon in the isolated perfused mouse liver.

CONCLUSION

The glucagon-induced secretion of FGF21 and GDF15 is augmented in MASLD and may depend on insulin. Thus, glucagon receptor agonism may augment its metabolic benefits in patients with MASLD through enhanced secretion of FGF21 and GDF15.

Для цитирования: Richter Michael M, Kemp Ida M, Heebøll Sara, Winther-Sørensen Marie, Kjeldsen Sasha A S, Jensen Nicole J, Nybing Janus D, Linden Frederik H, Høgh-Schmidt Erik, Boesen Mikael P, Madsbad Sten, Schiødt Frank Vinholt, Nørgaard Kirsten, Schmidt Signe, Gluud Lise Lotte, Haugaard Steen B, Holst Jens J, Nielsen Søren, Rungby Jørgen, Wewer Albrechtsen Nicolai J. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms.. Metabolism: clinical and experimental. 2024. DOI: 10.1016/j.metabol.2024.155915.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.